Xencor, Inc Finite-Lived Intangible Asset, Expected Amortization, after Year Five
Xencor, Inc (XNCR) had Finite-Lived Intangible Asset, Expected Amortization, after Year Five of $1.68 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive · last filed 2026-02-25
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $1.68M.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $3.20M.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $3.76M.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $3.18M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, after Year Five |
|---|---|
| 2025-12-31 | $1.68M 10-K · filed 2026-02-25 |
| 2024-12-31 | $3.20M 10-K · filed 2025-02-27 |
| 2023-12-31 | $3.76M 10-K/A · filed 2025-02-24 |
| 2022-12-31 | $3.18M 10-K · filed 2023-02-27 |
| 2021-12-31 | $3.21M 10-K · filed 2022-02-24 |
| 2020-12-31 | $3.21M 10-K · filed 2021-02-24 |
| 2019-12-31 | $2.37M 10-K · filed 2020-02-25 |
| 2018-12-31 | $1.92M 10-K · filed 2019-02-26 |
| 2017-12-31 | $2.36M 10-K · filed 2018-02-28 |
| 2016-12-31 | $2.29M 10-K · filed 2017-03-01 |
| 2015-12-31 | $2.39M 10-K · filed 2016-03-08 |
| 2014-12-31 | $2.41M 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |